Literature DB >> 9670108

The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats.

E Chabielska1, R Pawlak, J Golatowski, W Buczko.   

Abstract

The mechanism by which ACE-Is (angiotensin converting enzyme inhibitors) reduces the rate of coronary thrombosis among patients with left ventricular dysfunction is not known. A potential interaction between the renin-angiotensin system (RAS) and the thrombotic process has been suggested. The goal of the present study was to evaluate the antithrombotic action of drugs which block the RAS by different mechanisms; captopril (50 mg/kg p.o.)-the angiotensin converting enzyme inhibitor and losartan (30 mg/kg p.o.)-the selective AT1 receptor antagonist. The normotensive rats were treated in acute or chronic manner (7 days) and then the arterial thrombosis was induced by insertion of a loop-shaped cannula into the abdominal aorta. The occlusion time (the period during which the loop was totally occluded by thrombus) was significantly prolonged in comparison with the control groups after chronic treatment with captopril (by 46%; p < 0.01) and losartan (by 42%; p < 0.05). Our results provide experimental evidence that the drugs blocking RAS exert an antithrombotic effect in the arterial thrombosis model in rats. This effect was independent from changes in blood pressure and primary hemostasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670108

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  4 in total

Review 1.  New insights into the renin-angiotensin system and hypertensive renal disease.

Authors:  A B Fogo
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

2.  Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats.

Authors:  Marzena Wojewodzka-Zelezniakowicz; Wioleta Kisiel; Karol Kramkowski; Anna Gromotowicz-Poplawska; Agnieszka Zakrzeska; Adrian Stankiewicz; Patrycjusz Kolodziejczyk; Janusz Szemraj; Jerzy Robert Ladny; Ewa Chabielska
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-05-11       Impact factor: 1.636

3.  Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease.

Authors:  Young Kwang Chae; Danai Khemasuwan; Anastasios Dimou; Stefan Neagu; Lakshmi Chebrolu; Shikha Gupta; Alejandra Carpio; Jongoh Kim; Jeong Hyun Yun; Athanasios Smyrlis; Alan Friedman; William Tester
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

4.  Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.

Authors:  Areej Mohamed Ateya; Nagwa A Sabri
Journal:  J Med Virol       Date:  2020-11-22       Impact factor: 20.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.